Session Type
Meeting
Search Results for immunotherapy
Abstract Number: 819
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Case Presentation: A 77 year old man with stage IIIC mucosal melanoma, hypothyroidism, HTN and COPD presents from an outside hospital with two months of rapidly progressive altered mental status. He was diagnosed with melanoma of the oral palate, left parotid gland and neck one year ago, and underwent two cycles of ipilimumab (ipi) and […]
Abstract Number: 829
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Case Presentation: A 77 year old man with adenocarcinoma of the lung s/p chemotherapy and radiation presented to the Orthopedics service with hip pain & a left femoral lytic lesion.Soon after his IR-guided femur biopsy, medicine consult was called for ? cellulitis. Patient had new left 2nd toe pain, ankle pain, & knee pain, with […]
Abstract Number: E32
SHM Converge 2022
Case Presentation: A 67-year-old woman with a history of metastatic squamous cell carcinoma of the lungs and plaque psoriasis presented with subacute pruritic and painful descaling lesions of the skin after pembrolizumab maintenance therapy (Figure 1.A). The lesions on the skin were erythematous and desquamating, worse in the upper extremities, lower extremities, abdomen, and trunk. […]
Abstract Number: L25
SHM Converge 2022
Case Presentation: An 81-year-old man with a history of paroxysmal atrial fibrillation and angiosarcoma on immunotherapy presented with acute onset of shortness of breath, chest pressure and lower extremity edema. He had been started on ipilimumab and nivolumab 1 year prior to presentation and had developed immune checkpoint inhibitor (ICI) thyroiditis, hepatitis, and pneumonitis while […]
Abstract Number: L46
SHM Converge 2022
Case Presentation: Immune checkpoint inhibitors have evolved into the conventional therapy regimen for many cancer types. The major categories of immune checkpoint inhibitors include monoclonal antibodies against cytotoxic T lymphocyte antigen (CTLA-4), programmed cell death protein-1 (PD-1) and programmed cell death ligand molecules (PD-L1). Pembrolizumab has been implicated in causing hepatitis Discussion: An 89-year-old Caucasian […]
Abstract Number: O37
SHM Converge 2022
Case Presentation: This is a case of a 72-year-old male with Stage III metastatic melanoma. The patient was started on combination immunotherapy with ipilimumab and nivolumab three months prior. He completed three cycles of treatment. He presented to the emergency department with complaints of fatigue and lethargy. Initial assessment of vitals showed hypotension, BP 95/61 […]
Abstract Number: P38
SHM Converge 2022
Case Presentation: 56-year-old Caucasian lady with a past medical history of recurrent stage 4 melanoma presented with nausea, vomiting, inadequate oral intake and weight loss of 20lbs over several weeks. She received nivolumab immunotherapy for one year and stopped 3-months prior to presentation due to stable lesions without recurrence. She also underwent an esophagogastroduodenoscopy (EGD) […]